Company Filing History:
Years Active: 2004-2007
Title: Innovations of Noe Erasga in PPAR Modulation
Introduction
Noe Erasga is a notable inventor based in Ann Arbor, MI (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate PPAR activity. With a total of 2 patents to his name, his work has the potential to impact therapeutic approaches for various metabolic disorders.
Latest Patents
Noe Erasga's latest patents focus on compounds that alter PPAR activity. The first patent describes compounds that modulate PPAR activity and methods of preparation. This invention relates to compounds that can be used as therapeutic agents for treating or preventing conditions such as dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia, and hyperinsulinemia in mammals. The patent also includes pharmaceutically acceptable salts of these compounds and methods for their preparation. The second patent similarly discloses compounds that alter PPAR activity, emphasizing their use in treating hyperlipidemia and hypercholesterolemia.
Career Highlights
Noe Erasga is currently associated with Warner-Lambert Company, where he continues to innovate in the pharmaceutical sector. His work is characterized by a strong focus on developing effective therapeutic agents that address critical health issues.
Collaborations
Noe has collaborated with notable colleagues such as Xue-min Cheng and Gary Frederick Filzen, contributing to a dynamic research environment that fosters innovation.
Conclusion
Noe Erasga's contributions to the field of pharmaceutical sciences through his patents on PPAR-modulating compounds highlight his role as a significant inventor. His work not only advances scientific knowledge but also holds promise for improving health outcomes in various metabolic disorders.